Blanco-Sixtos E, Conde-Castro B, Cacho-González A, Jaime-Suárez BM, Martínez-Sánchez JL

Language: Spanish
References: 13
Page: 181-187
PDF size: 420.59 Kb.

ABSTRACT

Computed tomography is a tool that has proven useful in monitoring gastrointestinal stromal tumors subjected to targeted therapy.
Objective: evaluate by tomography the response to targeted therapy if gastrointestinal stromal tumors in patients at the Siglo XXI Cancer Hospital, in accordance with Choi’s criteria.
Materials and methods: a retrospective study, from January 2009 through January 2014, of patients with confirmed diagnosis of gastrointestinal tumor, who also had tomographies; response to treatment was analyzed in accordance with Choi’s criteria.
Results: 31 patients were included, 61% received targeted therapy with imatinib and 38% imatinib and sunitinib as second line therapy, with follow-up of at least 6 months and at most annual. In accordance with Choi’s criteria, in 45.2% the response was complete, in 19.4% there was stable disease, in another 19.4% partial response, and in 16.1% progression of disease.
Conclusions: Choi’s criteria proved to be useful in evaluating treatment with targeted molecular therapy in patients with gastrointestinal stromal tumors.

REFERENCES

1. Medrano G, Torres V, González R. Características clínicas de los tumores del estroma gastrointestinal. Cirujano general 2008;30(Suplemento 1).

2. Muñoz TC, Sabah TS, Navarro RA y cols. Tumores del estroma gastrointestinal (GIST): Revisión de la literatura. Gastroenterología Latinoamericana 2006;17(1):43-51.

3. Bensimhon D, Soyer P, Boudiaf M, et al. Imaging Of Gastrointestinal Stromal Tumors. Journal de Radiologie 2009;90(4):469-480.

4. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.

5. Hui C, Yun Z, Ming W, Dan-ping SH, et al. Pronostic analiysus of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease. Chinese Medical Journal 2010;132(2):131-136.

6. Rabin I, Chikman B, Lavy R, et al. Gastrointestinal Stromal Tumors: A 19 Year Experience. IMAJ 2009;12(11):98-102.

7. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008;3:557-86.

8. Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M. From the Archives of the AFIP Gastrointestinal Stromal Tumors: Radiologic Features with Pathologic Correlation. RadioGraphics 2003;23:283-304.

9. Nowain A, Bhakta H, Pais S, et al.: Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol 2005;20(6):818-24.

10. Pérez-Morales AG, Ruiz-Juárez IZ, Roesch DF y cols. Tumores del estroma gastrointestinal. Presentación de una serie de tres casos de localización gástrica. Cirujano General 2007;29(1):50-53.

11. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753–1759.

12. Toyokawa T, Yamashita Y, Yamamoto A, et al. Clinical experience of Imatinib mesylate for metastatic or recurrente gastrointestinal stromal tumor. Gan To Kagaku Ryoho 2014;41(1):55-8.

13. Haesun Choi, et al. Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria. Journal of clinical Oncology 2007;25(13):1753-1759.